Here, we reported, for the first time, that combined treatment with FGFR1 and PLK1 inhibitors evokes synergistic cytotoxic activity in KRAS‐mutant lung and pancreatic cancer models in vitro and in vivo. This evidence concerns the gene KRAS and familial pancreatic carcinoma.